Be Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 5.01 Cr
as on 23-10-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 20.00 Cr
as on 23-10-2024
- Revenue -94.44%
(FY 2023)
- Profit 100.02%
(FY 2023)
- Ebitda 99.26%
(FY 2023)
- Net Worth 108.01%
(FY 2023)
- Total Assets -96.56%
(FY 2023)
About Be Pharmaceuticals
The Corporate was formerly known as Akorn India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.01 Cr.
The company has closed loans amounting to ₹20.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mahima Datla, Mahipal Saddi, and Rudaraju Kumar serve as directors at the Company.
- CIN/LLPIN
U24100TG2011PTC148362
- Company No.
262196
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2011
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Be Pharmaceuticals Private Limited offer?
Be Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Eye Drops, Ayurvedic,Herbal Products & Medicine, Pain Balm & Ointments, Anti Cancer Medicines, Doxorubicin Hydrochloride Injection, Injectable Products, Anti Infective Drugs & Medicines, Antibacterial Drugs, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Be Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahima Datla  | Director | 14-Aug-2020 | Current |
| Mahipal Saddi | Director | 26-Aug-2020 | Current |
| Rudaraju Kumar | Director | 14-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Be Pharmaceuticals.
Be Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 94.44% decrease. The company also saw a substantial improvement in profitability, with a 100.02% increase in profit. The company's net worth Soared by an impressive increase of 108.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Be Pharmaceuticals?
In 2023, Be Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Vaxenic India Private LimitedActive 9 years 10 months
Mahima Datla and Rudaraju Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 25 Jul 2014 | ₹20.00 Cr | Satisfied |
How Many Employees Work at Be Pharmaceuticals?
Be Pharmaceuticals has a workforce of 222 employees as of Aug 14, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Be Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Be Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
